Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lemzoparlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lemzoparlimab overview
TJC-4 (lemzoparlimab) is under development for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma or indolent B-cell lymphoma, relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome, primary mediastinal b-cell lymphoma, non-small-cell lung carcinoma (NSCLC), epithelial ovarian cancer, fallopian tube and primary peritoneal cancer and for solid tumor. The drug candidate is developed based on hybridoma and phage display technologies. It acts by targeting CD47. It is administered through intravenous route. It was also under development for the treatment of non-Hodgkin's lymphoma, urothelial (bladder) cancer.
It was also under development for the treatment of melanoma, gastric cancer, head and neck squamous cell carcinoma, relapsed and refractory and newly diagnosed multiple myeloma,
AbbVie overview
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers. The company has operations in the Americas, Asia-Pacific, Europe, the Middle East and Africa. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of Lemzoparlimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
